Paper
The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family.
Published May 24, 2006 · L. Gibson, S. F. Hastings, I. McPhee
European journal of pharmacology
Q1 SJR score
131
Citations
6
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro Study
Rigorous Journal
Highly CitedStudy Snapshot
Ibudilast preferentially inhibits PDE3A, PDE4, PDE10, and PDE11, potentially benefiting neurological conditions like ischemic stroke and bronchial asthma.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
The PDE superfamily offers potential targets for developing selective therapeutic agents that restore normal intracellular signaling and potentially improve treatment for inflammation, neurodegeneration, and cancer.
2006·873citations·C. Lugnier·Pharmacology & therapeutics
Pharmacology & therapeutics
Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology
PDE11 plays a role in spermatogenesis and fertilization potential, with reduced sperm concentration, rate of forward progression, and percentage of live spermatozoa in PDE11/ mice.
2005·75citations·C. Wayman et al.·International Journal of Impotence Research
International Journal of Impotence Research
Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model
Ibudilast, a phosphodiesterase inhibitor, can potentially be a novel alternative therapy for Krabbe's disease by reducing oligodendrocyte apoptosis and mildening demyelination in a mouse model.
2005·47citations·Kuriko Kagitani-Shimono et al.·Journal of Neuroinflammation
Journal of Neuroinflammation
PDE10A inhibition reverses subchronic PCP‐induced deficits in attentional set‐shifting in rats
Subchronic PCP administration in rats models cognitive deficits in schizophrenia, and PDE10A inhibition may be an effective therapeutic route to improve executive function deficits associated with schizophrenia.
2005·201citations·J. Rodefer et al.·European Journal of Neuroscience
European Journal of Neuroscience
Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis
Ibudilast shows potential as a promising therapy for multiple sclerosis by regulating Th1/Th2 balance and increasing natural killer T cells in MS patients.
2004·55citations·Juan Feng et al.·Multiple Sclerosis
Multiple Sclerosis
Citations
Ibudilast Protects Retinal Bipolar Cells From Excitotoxic Retinal Damage and Activates the mTOR Pathway.
Ibudilast effectively protects inner retinal neurons from damage and activates the mTOR pathway, showing potential for future clinical translation.
2025·0citations·Sumaya N. Hamadmad et al.·Glia
Glia
Therapeutic targeting of neuroinflammation in methamphetamine use disorder.
Targeting neuroinflammation in methamphetamine use disorders shows promise in mitigating cognitive impairment and neurodegeneration, offering a potential therapeutic strategy for improving outcomes.
2024·0citations·Natasha Jeffery et al.·Future medicinal chemistry
Future medicinal chemistry
Morphine self-administration is inhibited by the antioxidant N‐acetylcysteine and the anti-inflammatory ibudilast; an effect enhanced by their co-administration
Combining NAC and ibudilast effectively reduces voluntary morphine intake, potentially benefiting treatment of opioid use disorders.
2024·0citations·M. E. Quintanilla et al.·PLOS ONE
PLOS ONE
Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD
STP1 is well-tolerated and shows indirect target engagement in ASD brain regions of interest, but clinical improvements were not statistically significant.
2024·1citation·Craig A. Erickson et al.·Biomedicines
Biomedicines
Therapeutic perspectives on PDE4B inhibition in adipose tissue dysfunction and chronic liver injury.
PDE4 inhibitors show potential in treating chronic liver disease by targeting inflammation and metabolism in various organ systems, potentially benefiting patients beyond the liver.
2024·0citations·Dalton W. Staller et al.·Expert opinion on therapeutic targets
Expert opinion on therapeutic targets
Sex differences in neural response to an acute stressor in individuals with an alcohol use disorder.
Sex differences in the brain's response to social-evaluative stress exist in individuals with alcohol use disorder, with females showing higher amygdala activation and greater activation in certain brain regions.
2024·1citation·E. Grodin et al.·Alcohol, clinical & experimental research
Alcohol, clinical & experimental research
Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis
Emerging ALS therapeutics in phase II & III clinical trials show promise, particularly targeting genetic and retroviral causes and diverse downstream pathways.
2024·2citations·Xiaoyan Li et al.·Expert Opinion on Emerging Drugs
Expert Opinion on Emerging Drugs
Neuroimmune modulators as novel pharmacotherapies for substance use disorders
Neuroimmune modulators show promise in reducing drug-seeking behavior and preventing relapse in substance use disorders, with potential for both stand-alone and adjunctive treatments.
2024·1citation·E. Grodin·Brain, Behavior, & Immunity - Health
Brain, Behavior, & Immunity - Health